Palladia

• PALLADIA is an oral tablet indicated for the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumours (MCT) with or without regional lymph node involvement in dogs.
• PALLADIA is a member of a new class of anticancer agents called receptor tyrosine kinase inhibitors that have proven effective in the treatment of some human cancers.
• The first ACVM-approved small molecule inhibitor developed specifically for the treatment of canine mast cell tumours¹.

• PALLADIA is a multi-kinase RTKi that selectively blocks the activity of multiple RTKs on cancer and endothelial cells.
• It inhibits the activity of VEGFR2 (vascular endothelial growth factor receptor 2), PDGFR (platelet-derived growth factor receptor)² and (stem cell factor receptor) c-kit, which confers it both direct antitumour and antiangiogenic activity.
• PALLADIA can be administered at home by a dog’s owner.
• In dogs treated with PALLADIA, 59.5% of mast cell tumours (MCT) disappeared, regressed, or stabilised^3,4.

Each PALLADIA tablet contains 10 mg, 15 mg or 50 mg of toceranib as toceranib phosphate. Each tablet is marked with the tablet strength on one side and the Zoetis logo on the other.

The initial dose is 3.25 mg/kg body weight administered orally every second day. The dose may be adjusted based on veterinary assessments of the dog’s clinical status. Monitoring should be conducted weekly for the first six weeks and, thereafter, once every six weeks.

For complete prescribing information, please refer to product labelling.

DO NOT BREAK OR CRUSH TABLETS.

Wear gloves to avoid skin contact with tablets, and the faeces, urine, and vomit of PALLADIA-treated dogs. The tablets must be administered whole and must not be broken or ground. If a broken tablet is rejected by the dog after chewing, it should be disposed of. Hands should be thoroughly washed with soap and water following handling of the product and disposal of vomit, urine, or faeces of PALLADIA-treated dogs.

Pregnant women should not administer PALLADIA as toceranib may cause birth defects. For pregnant women, accidental ingestion of PALLADIA may have adverse effects on pregnancy. Women of child bearing age and nursing mothers are advised to wear gloves when administering PALLADIA. Children should not come into contact with this drug. Keep children away from vomit, faeces and urine of treated dogs.

Store below 30^oC (Room temperature).

Zoetis New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 963 847, Fax: 0800 628 629. PALLADIA is a registered trade mark of Zoetis Inc. or its subsidiaries. ACVM No. A10834. RVM; Available only under Veterinary Authorisation.

References:

1. London CA et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003; 9: 2755-68.
2. Liao, A.T. et al. (2002). ‘Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors’. Blood 100(2), pp. 585-593.
3. London CA, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 2009 15(11):3856-3865.
4. Data on file; Zoetis study number 1963C-60-04-688.

For technical enquiries please phone Zoetis Technical Services on 0800 650 277.

• PALLADIA - ANZ Approved Leaflet.pdf
• Zoetis Safety Data Sheets